🔗 Share this article

An underground market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.

Investigational Drug Gaining Traction Via Social Media

The experimental drug, which remains in research studies, is being advertised by online personalities for its supposed fat-burning properties. Followers are urged to message these accounts privately for supplier links, while also obtaining promotional offers.

Active Trade on Messaging Platforms

Additionally, a flourishing market exists on Telegram, where communities with thousands of members share “before and after” photos, administration instructions and claims of next-day UK delivery. Sellers market the substance there before redirecting buyers to WhatsApp for purchases.

Understanding The Experimental Drug

This medication is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients lose up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Healthcare Experts Voice Worries

However, doctors and pharmacists have warned that the distribution of what remains an unapproved drug in the United Kingdom is a cause for concern and could lead to individuals injecting substances of unknown origin.

Some experts said the demand for the experimental drug could be connected to the increasing price of licensed weight loss products such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unlicensed medication that must not be promoted or supplied for human use under the Human Medicines Regulations 2012.

Some content creators attempt to sidestep the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but promotion and distribution can still breach medicines, advertising, and consumer regulations, potentially leading to fines, legal action or prison.

Platform Reaction and Content Elimination

According to the social media company, the service has taken down problematic material and prohibited associated keywords and query recommendations. The company said it was dedicated to maintaining the platform safe and allocating resources in strengthening enforcement strategies.

Digital Trading Activities

Research also found groups with up to nine thousand members marketing retatrutide using the platform's integrated search feature, which functions like a online catalog. Typing “retatrutide” instantly brings up groups with thousands of members, filled with images of weight loss, positive reviews and step-by-step instructions for mixing or administering at residence.

Within moments of entering one community, a seller posted WhatsApp details, where most transactions occur. The vendor provided an instruction manual and guaranteed shipping within two days. When questioned whether the substance was genuine, one vendor responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one inquired about weight, medical conditions or previous experience.

Product Details and Costs

Inside these groups, posts display dark colored packages with postal service stickers, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with purified liquid, or ready-to-use pens typically sold at 160 pounds for 20mg. When asked how long a injector should be used, sellers give conflicting responses ranging from a several days to “depends on your body”.

Service Oversight and Security Measures

A representative for the messaging service said it regularly monitored harmful content on its platform including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are administering materials they can’t verify. Even if the research behind this drug is sound, these online products may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service connected the surge in interest to current cost increases for approved slimming drugs such as Mounjaro. “With prices rising, individuals are turning to online platforms. But counterfeit injections are extremely dangerous. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she explained.

Her team has already encountered patients harmed by self-injection from unverified suppliers. “We understand the frustration, but buying from messaging apps or communication platforms is gambling with your health,” stated Wyllie. “These materials could be impure or incorrectly dosed.”

Producer Statement

A representative from the pharmaceutical company stated the substance was in third stage research studies and had not been evaluated or approved by any government authority anywhere in the world. “Therefore at this point no one can sell [it] for personal consumption,” they said, adding that any item “misleadingly claiming itself as a company experimental substance not yet approved … may subject users to possibly serious medical dangers”.